cb984 antikoerper, ptprm antikoerper, zgc:110218 antikoerper, PTPRM antikoerper, p-ptp-mu antikoerper, ptprl1 antikoerper, r-ptpu antikoerper, rptpm antikoerper, rptpu antikoerper, PTPRL1 antikoerper, R-PTP-MU antikoerper, RPTPM antikoerper, RPTPU antikoerper, hR-PTPu antikoerper, RPTPmu antikoerper, mKIAA4044 antikoerper, protein tyrosine phosphatase, receptor type, M, a antikoerper, protein tyrosine phosphatase, receptor type M antikoerper, protein tyrosine phosphatase, receptor type, M, b antikoerper, receptor-type tyrosine-protein phosphatase mu antikoerper, protein tyrosine phosphatase, receptor type, M antikoerper, ptprma antikoerper, PTPRM antikoerper, ptprmb antikoerper, ptprm antikoerper, LOC100550127 antikoerper, LOC100564083 antikoerper, Ptprm antikoerper
Hintergrund
PTP mu, a R2A receptor protein tyrosine phosphatase, is composed of an extracellular segment containing a MAM domain, an immunoglobulin domain and four fibronectin type III repeats, a transmembrane segment, and two intracellular protein phosphatase domains. PTP mu has been shown to affect cell-cell aggregation, regulate cardiac myocyte Kv1.5 channel expression, and promote neurite outgrowth of retinal ganglion cells. The human PTP mu gene is localized on chromosome 18pter-q11, a region with frequent abnormalities implicated in human cancer. PTP mu may be important in responses to pathological conditions associated with the loss of cell-cell interactions in the heart.